| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0000002 | Mitochondrial genome maintenance | Decreases phenotype | PMID:34520793 |
| GO:0000050 | Urea cycle | Affects phenotype | PMID:31454128 |
| GO:0001659 | Temperature homeostasis | Affects phenotype | PMID:30009846 |
| GO:0001774 | Microglial cell activation | Increases phenotype | PMID:35741090 |
| GO:0001836 | Release of cytochrome c from mitochondria | Increases phenotype | PMID:27553674 |
| GO:0001964 | Startle response | Affects phenotype | PMID:30395337; PMID:30850843 |
| GO:0002523 | Leukocyte migration involved in inflammatory response | Increases phenotype | PMID:25798648; PMID:28595958 |
| GO:0004035 | Alkaline phosphatase activity | Increases phenotype | PMID:28987327; PMID:33396045; PMID:35678313 |
| GO:0004069 | L-aspartate:2-oxoglutarate aminotransferase activity | Increases phenotype | PMID:33396045; PMID:35678313 |
| GO:0004096 | Catalase activity | Affects phenotype | PMID:33396045 |
| GO:0004129 | Cytochrome-c oxidase activity | Decreases phenotype | PMID:17304643 |
| GO:0004175 | Endopeptidase activity | Decreases phenotype | PMID:38040083 |
| GO:0004197 | Cysteine-type endopeptidase activity | Decreases phenotype | PMID:38040083 |
| GO:0004303 | Estradiol 17-beta-dehydrogenase activity | Decreases phenotype | PMID:34896426 |
| GO:0004364 | Glutathione transferase activity | Increases phenotype | PMID:30884102; PMID:33396045 |
| GO:0004457 | Lactate dehydrogenase activity | Affects phenotype | PMID:35678313 |
| GO:0004602 | Glutathione peroxidase activity | Increases phenotype | PMID:30884102; PMID:31454128; PMID:33396045; PMID:35678313; PMID:35678313 |
| GO:0004784 | Superoxide dismutase activity | Affects phenotype | PMID:28595958; PMID:28595958; PMID:31454128; PMID:30884102; PMID:31454128; PMID:35678313 |
| GO:0006601 | Creatine biosynthetic process | Increases phenotype | PMID:28595958 |
| GO:0006641 | Triglyceride metabolic process | Affects phenotype | PMID:33396045; PMID:33396045; PMID:35678313; PMID:35678313 |
| GO:0006750 | Glutathione biosynthetic process | Increases phenotype | PMID:24217896; PMID:30884102; PMID:31454128 |
| GO:0006754 | Atp biosynthetic process | Decreases phenotype | PMID:27553674 |
| GO:0006809 | Nitric oxide biosynthetic process | Increases phenotype | PMID:25439240; PMID:31454128 |
| GO:0006811 | Monoatomic ion transport | Increases phenotype | PMID:2167745 |
| GO:0006915 | Apoptotic process | Affects phenotype | PMID:24217896; PMID:26588882; PMID:27553674 |
| GO:0006919 | Activation of cysteine-type endopeptidase activity involved in apoptotic process | Increases phenotype | PMID:30247739 |
| GO:0006974 | Cellular response to dna damage stimulus | Increases phenotype | PMID:25439240; PMID:28595958 |
| GO:0007033 | Vacuole organization | Increases phenotype | PMID:28595958 |
| GO:0007283 | Spermatogenesis | Decreases phenotype | PMID:25299849; PMID:34896426 |
| GO:0007340 | Acrosome reaction | Decreases phenotype | PMID:33396045; PMID:34896426 |
| GO:0007611 | Learning or memory | Decreases phenotype | PMID:30850843; PMID:32976580 |
| GO:0007612 | Learning | Decreases phenotype | PMID:25359175 |
| GO:0007626 | Locomotory behavior | Increases phenotype | PMID:25630971 |
| GO:0008137 | Nadh dehydrogenase (ubiquinone) activity | Decreases phenotype | PMID:27553674 |
| GO:0008202 | Steroid metabolic process | Affects phenotype | PMID:38176580 |
| GO:0008203 | Cholesterol metabolic process | Affects phenotype | PMID:35678313 |
| GO:0008219 | Cell death | Increases phenotype | PMID:16644695; PMID:28595958 |
| GO:0008283 | Cell population proliferation | Decreases phenotype | PMID:26588882 |
| GO:0008285 | Negative regulation of cell population proliferation | Increases phenotype | PMID:32800223; PMID:32949729; PMID:34520793 |
| GO:0010890 | Positive regulation of sequestering of triglyceride | Increases phenotype | PMID:28119079; PMID:35715053 |
| GO:0010917 | Negative regulation of mitochondrial membrane potential | Increases phenotype | PMID:34520793; PMID:38040083 |
| GO:0010940 | Positive regulation of necrotic cell death | Increases phenotype | PMID:39971138 |
| GO:0014046 | Dopamine secretion | Decreases phenotype | PMID:30850843 |
| GO:0016042 | Lipid catabolic process | Increases phenotype | PMID:25439240; PMID:28595958; PMID:28595958; PMID:31454128; PMID:31454128; PMID:33396045; PMID:33396045; PMID:35678313; PMID:35678313; PMID:35741090 |
| GO:0016049 | Cell growth | Decreases phenotype | PMID:24217896 |
| GO:0016209 | Antioxidant activity | Decreases phenotype | PMID:25798648 |
| GO:0021872 | Forebrain generation of neurons | Decreases phenotype | PMID:25359175 |
| GO:0030283 | Testosterone dehydrogenase [nad(p)] activity | Decreases phenotype | PMID:33396045 |
| GO:0030335 | Positive regulation of cell migration | Increases phenotype | PMID:32800223 |
| GO:0030534 | Adult behavior | Affects phenotype | PMID:30009846 |
| GO:0031223 | Auditory behavior | Affects phenotype | PMID:30395337 |
| GO:0031398 | Positive regulation of protein ubiquitination | Increases phenotype | PMID:34520793 |
| GO:0031987 | Locomotion involved in locomotory behavior | Increases phenotype | PMID:31683416 |
| GO:0032760 | Positive regulation of tumor necrosis factor production | Increases phenotype | PMID:27655349 |
| GO:0033148 | Positive regulation of intracellular estrogen receptor signaling pathway | Increases phenotype | PMID:25449125 |
| GO:0034101 | Erythrocyte homeostasis | Decreases phenotype | PMID:33385678 |
| GO:0034418 | Urate biosynthetic process | Affects phenotype | PMID:31454128 |
| GO:0034440 | Lipid oxidation | Increases phenotype | PMID:26013673 |
| GO:0035584 | Calcium-mediated signaling using intracellular calcium source | Decreases phenotype | PMID:31166131 |
| GO:0036269 | Swimming behavior | Affects phenotype | PMID:31683416 |
| GO:0042403 | Thyroid hormone metabolic process | Affects phenotype | PMID:31683416 |
| GO:0042416 | Dopamine biosynthetic process | Affects phenotype | PMID:26588882; PMID:30884102 |
| GO:0042421 | Norepinephrine biosynthetic process | Affects phenotype | PMID:30850843; PMID:30884102 |
| GO:0042427 | Serotonin biosynthetic process | Affects phenotype | PMID:30884102 |
| GO:0042554 | Superoxide anion generation | Increases phenotype | PMID:28987327 |
| GO:0043065 | Positive regulation of apoptotic process | Increases phenotype | PMID:25299849; PMID:32800223; PMID:33385678; PMID:34520793; PMID:39971138 |
| GO:0045429 | Positive regulation of nitric oxide biosynthetic process | Increases phenotype | PMID:26013673 |
| GO:0045454 | Cell redox homeostasis | Decreases phenotype | PMID:26013673; PMID:35741090 |
| GO:0045773 | Positive regulation of axon extension | Increases phenotype | PMID:31166131 |
| GO:0046034 | Atp metabolic process | Affects phenotype | PMID:32949729 |
| GO:0046209 | Nitric oxide metabolic process | Affects phenotype | PMID:35678313 |
| GO:0046323 | Glucose import | Affects phenotype | PMID:29380240 |
| GO:0046415 | Urate metabolic process | Affects phenotype | PMID:28595958 |
| GO:0046449 | Creatinine metabolic process | Affects phenotype | PMID:31454128 |
| GO:0046878 | Positive regulation of saliva secretion | Increases phenotype | PMID:30395337 |
| GO:0048102 | Autophagic cell death | Affects phenotype | PMID:26588882 |
| GO:0048240 | Sperm capacitation | Decreases phenotype | PMID:33396045; PMID:34896426 |
| GO:0050729 | Positive regulation of inflammatory response | Increases phenotype | PMID:39971138 |
| GO:0050768 | Negative regulation of neurogenesis | Decreases phenotype | PMID:32976580 |
| GO:0050890 | Cognition | Decreases phenotype | PMID:30850843 |
| GO:0050996 | Positive regulation of lipid catabolic process | Increases phenotype | PMID:33385678; PMID:39971138 |
| GO:0051646 | Mitochondrion localization | Affects phenotype | PMID:34520793 |
| GO:0051881 | Regulation of mitochondrial membrane potential | Affects phenotype | PMID:17304643; PMID:27553674 |
| GO:0060291 | Long-term synaptic potentiation | Increases phenotype | PMID:30850843 |
| GO:0061370 | Testosterone biosynthetic process | Affects phenotype | PMID:34896426; PMID:36053783 |
| GO:0061739 | Protein lipidation involved in autophagosome assembly | Increases phenotype | PMID:34520793 |
| GO:0070059 | Intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | Increases phenotype | PMID:31841155 |
| GO:0070585 | Protein localization to mitochondrion | Increases phenotype | PMID:28987327 |
| GO:0071211 | Protein targeting to vacuole involved in autophagy | Affects phenotype | PMID:34520793 |
| GO:0071902 | Positive regulation of protein serine/threonine kinase activity | Increases phenotype | PMID:28119079 |
| GO:0102727 | 3beta-hydroxysteroid dehydrogenase activity | Decreases phenotype | PMID:33396045; PMID:34896426; PMID:36053783 |
| GO:0140059 | Dendrite arborization | Increases phenotype | PMID:31166131 |
| GO:0150078 | Positive regulation of neuroinflammatory response | Increases phenotype | PMID:35741090 |
| GO:1900825 | Regulation of membrane depolarization during cardiac muscle cell action potential | Decreases phenotype | PMID:30868487 |
| GO:1901216 | Positive regulation of neuron death | Increases phenotype | PMID:25630971 |
| GO:1901526 | Positive regulation of mitophagy | Increases phenotype | PMID:34520793 |
| GO:1901670 | Negative regulation of superoxide dismutase activity | Increases phenotype | PMID:39971138 |
| GO:1901799 | Negative regulation of proteasomal protein catabolic process | Increases phenotype | PMID:34520793 |
| GO:1902237 | Positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway | Increases phenotype | PMID:25359175 |
| GO:1902512 | Positive regulation of apoptotic dna fragmentation | Increases phenotype | PMID:26013673 |
| GO:1902552 | Negative regulation of catalase activity | Increases phenotype | PMID:39971138 |
| GO:1903223 | Positive regulation of oxidative stress-induced neuron death | Increases phenotype | PMID:26013673 |
| GO:1903381 | Regulation of endoplasmic reticulum stress-induced neuron intrinsic apoptotic signaling pathway | Increases phenotype | PMID:25359175 |
| GO:1903409 | Reactive oxygen species biosynthetic process | Increases phenotype | PMID:24217896; PMID:26588882; PMID:28987327 |
| GO:1903428 | Positive regulation of reactive oxygen species biosynthetic process | Increases phenotype | PMID:25798648; PMID:32800223; PMID:35741090; PMID:39971138 |
| GO:1903607 | Cytochrome c biosynthetic process | Decreases phenotype | PMID:17304643 |
| GO:1903779 | Regulation of cardiac conduction | Affects phenotype | PMID:25798648 |
| GO:1903784 | Positive regulation of sodium ion import across plasma membrane | Increases phenotype | PMID:27655349 |
| GO:1903787 | Negative regulation of glutathione biosynthetic process | Increases phenotype | PMID:33385678; PMID:39971138 |
| GO:1904179 | Positive regulation of adipose tissue development | Increases phenotype | PMID:35715053 |
| GO:1904456 | Negative regulation of neuronal action potential | Increases phenotype | PMID:31166131 |
| GO:1905629 | Positive regulation of serotonin biosynthetic process | Increases phenotype | PMID:33385678 |
| GO:1990138 | Neuron projection extension | Increases phenotype | PMID:28943602 |
| GO:2000748 | Positive regulation of defecation rhythm | Increases phenotype | PMID:33385678 |
| GO:2000786 | Positive regulation of autophagosome assembly | Increases phenotype | PMID:34520793 |
| GO:2000854 | Positive regulation of corticosterone secretion | Increases phenotype | PMID:33385678 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.